In this episode of the ISHLT Voices podcast, hosted by Natera, you’ll hear a discussion on the need for noninvasive surveillance options for single lung transplantation and the role that the Prospera Lung donor derived cell free DNA (dd-cfDNA) test can play. There are inherent, increased risks and challenges associated with management of single lung transplantation over double lung. Monitoring through invasive transbronchial biopsy procedures (TBBx) is often not the best option for these high-risk, frail patients. In this podcast, notable transplant pulmonologists Drs. Rosenheck and Arunachalam highlight the need in the single lung population for noninvasive surveillance options. The Prospera Lung donor derived cell free DNA (dd-cfDNA) test has been validated in single and double lung transplants with emerging data in support of clinical utility. The expert speakers also discuss the recently published data in support of dd-cfDNA usage in the single lung transplant population from the SLAM study.   Justin Rosenheck, DOAssistant Professor of Internal Medicine Ohio State University | Columbus, OH USA Ambalavanan Arunachalam, MDAssistant Professor, Medicine (Pulmonary and Critical Care) Northwestern Medicine | Chicago, IL USA The content of this podcast was developed entirely by ISHLT's industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

Presented by Kamada In this episode of the ISHLT Voices podcast, hosted by Kamada, you’ll hear a discussion on the utilization of Cytomegalovirus Immune Globulin (CMV IgG) in solid organ transplantation (SOT). First, a focused overview of CMV IgG, including what they are, how they are made, and their role in SOT. The experts describe the differences between hyperimmune globulins like CMV IgG and standard immune globulins (IVIG). Then, enjoy a discussion from the experts on two recently presented poster highlighting CMV IgG use in lung transplantation and the need for new emerging data. SPEAKERS: Martin Zamora, MD Medical Director of Lung Transplantation  Advent Health | Orlando, FL USA             Lorenzo Zaffiri, MD, PhD Medical Director of Lung Transplantation  Emory University | Atlanta, GA USA             Robert Gottlieb, MD, PhD, FACC Transplant Cardiologist  Baylor Scott White | Dallas, TX USA             The content of this podcast was developed entirely by our industry partner, Kamada. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.   This episode was created for ISHLT Voices and sponsored by Kamada.  

Presented by Natera Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does. In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation. Philip F. Halloran, MD, PhD, FRCP(C), OC, FRSC Professor of Medicine & Medical Microbiology and Immunology Director, Alberta Transplant Applied Genomics Centre University of Alberta Edmonton, AB Canada Kieran Halloran, MD, MSc Transplant Pulmonologist Associate Professor University of Alberta Edmonton, AB Canada Patrick Gauthier, PhD Senior Data Scientist Alberta Transplant Applied Genomics Centre Edmonton, AB Canada   This episode was created for ISHLT Voices and sponsored by Natera. The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.

Presented by Zambon USA ISHLT Voices returns with another podcast presented by Zambon USA exploring bronchiolitis obliterans syndrome (BOS). BOS is one of the most common forms of chronic lung transplant rejection, and in part three of this series, experts take a deep dive into CLAD phenotype differentiation, current gaps in diagnosis and management of BOS, emerging treatment strategies, and lastly, discuss the advances made in BOS diagnosis and management over the last decade. Steven Hays, MD Medical Director, Advanced Lung Disease and Lung Transplant Programs University of California, San Francisco San Francisco, CA USA Justin P. Rosenheck, DO Clinical Assistant Professor of Internal Medicine Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplant Program The Ohio State University Wexner Medical Center Columbus, OH USA This episode was created for ISHLT Voices and sponsored by Zambon USA, Ltd. The content of this industry-supported ISHLT Voices podcast is developed entirely by our industry partner, Zambon. This is not an official ISHLT educational program, and therefore is not eligible for CME under the ISHLT.

Presented by Natera In this episode of the ISHLT Voices podcast, Dr. Shri Deshpande, a cardiologist at the National Children’s Hospital in Washington, DC USA, discusses his work on improving the care of pediatric heart transplant patients.  Dr. Deshpande's research focuses on the use of cell-free DNA in monitoring transplant recipients for rejection. He explains that cell-free DNA, released when cells break down, can be detected in the bloodstream and used as a non-invasive screening tool to assess the health of transplanted organs.  The discussion covers the external validation of the Prospera™ assay by Natera, which has shown high negative predictive value and specificity, making it a promising tool for reducing the need for invasive biopsies and improving long-term transplant outcomes. Dr. Deshpande also highlights the potential for wider implementation of this technology in standard transplant care and ongoing research to optimize its use. Shriprasad Deshpande, MD Cardiologist Director, Advanced Cardiac Therapies Director, Heart Transplant Program National Children’s Hospital Washington, DC USA   This episode was created for ISHLT Voices and sponsored by Natera. The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.